A phase I/II study of percutaneous radiofrequency ablation for metastatic bone tumor (JIVROSG-0208)

A phase I/II study of percutaneous radiofrequency ablation for metastatic bone tumor (JIVROSG-0208) - Percutaneous radiofrequency ablation for metastatic bone tumor (JIVROSG-0208)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000047

Enrollment

Registered

2005-08-07

Start date

2004-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symptomatic metastatic bone tumor

Interventions

Radiofrequency ablation needle is percutaneouly inserted into the metastatic bone tumor and radiofrequency ablation is performed.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Symptomatic and uncontrollable metastatic bone tumor. 2) Histologically confirmed malignant lesion. 3) No influence of previous treatments. 4) Measurable lesion on CT or MRI. 5) Adequate cardiac, hepatic, renal, respiratory, and bone marrow functions. 6) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3. 7) Expected survival more than 4 weeks. 8) Written informed consent.

Exclusion criteria

Exclusion criteria: 1) Cardiac pacemaker. 2) Artery or nerve along the puncture route. 3) Pregnancy. 4) No symptom or VAS of less than 3.

Design outcomes

Primary

Measure	Time frame
Adverse events	—

Secondary

Measure	Time frame
Imrovement of symptom measured by Visual Analogue Scale at 1 week after the procedure.	—

Countries

Japan

Contacts

Public ContactYasuaki Arai

JIVROSG, Coordinating Office Division of Diagnostic Radiology, National Cancer Center Hospital

jivrosgoffice@ml.res.ncc.go.jp03-3542-2511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026